Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health Inc (NYSE: EVH) delivers transformative healthcare solutions through value-based care models and AI-powered technology. This news hub provides investors and healthcare professionals with essential updates on the company developments shaping modern care delivery.
Access authoritative coverage of EVH's strategic initiatives including specialty care management advancements, AI-driven clinical review systems, and partnerships with major health systems. Our curated news collection features earnings reports, regulatory filings, and analysis of operational milestones in oncology, cardiology, and musculoskeletal care management.
Key focus areas include updates on Evolent's proprietary platforms for total cost of care optimization, health plan administration innovations, and value-based payment model expansions. Stay informed about technological integrations like the Machinify Auth AI system that streamline clinical decision-making processes.
Bookmark this page for real-time updates on EVH's progress in aligning financial incentives with patient outcomes. Monitor how their integrated approach to population health management continues to redefine care delivery standards across healthcare networks.
Define Ventures, a major venture capital firm focusing on early-stage health tech companies, has appointed Bruce Broussard as venture partner. Broussard, former CEO and president of Humana, brings extensive experience in scaling companies and fostering innovation across various healthcare sectors. His role will involve guiding founders, shaping investment strategies, and strengthening partnerships with large healthcare organizations.
Broussard's decision to join Define Ventures is rooted in his belief in the firm's unique position to transform healthcare. His appointment follows that of Frank Williams, co-founder and former CEO of Evolent, who joined as venture partner earlier this year. Define Ventures, with $800 million in assets under management, partners with companies at seed, series A, and series B stages, including notable firms like Hims & Hers and Unite Us.
Evolent Health (NYSE: EVH) reported Q2 2024 results with revenue of $647.1 million, up 37.9% year-over-year. The company posted a net loss of $6.4 million and an Adjusted EBITDA of $52.0 million. Key highlights include:
- Net loss margin of (1.0)%
- Adjusted EBITDA margin of 8.0%
- Narrowed revenue outlook for full year 2024
- Updated 2024 Adjusted EBITDA guidance
- Reiterated confidence in achieving $300 million Adjusted EBITDA run rate exiting 2024
Evolent secured four new revenue agreements and expanded services with existing clients. The company expects Q3 2024 revenue between $615-$635 million and Adjusted EBITDA of $60-$68 million. Full-year 2024 guidance projects revenue of $2.56-$2.60 billion and Adjusted EBITDA of $230-$245 million.
Evolent Health (NYSE: EVH) will announce its Q2 2024 financial results on August 8, 2024, post-market close, followed by a conference call at 5 p.m. ET. Interested participants can access the live broadcast via Evolent's investor relations website or join the call by dialing 855.940.9467 (domestic) or 412.317.6034 (international), referencing the 'Evolent call'. An audio playback will be available on the website for 90 days post-call.
Evolent's executive team will also participate in investor conferences, including the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, and the 2024 Bernstein Disruptor Conference in New York on September 24, 2024. Webcasts for these events, if available, will be accessible through their investor relations site.
Evolent Health (EVH) has announced an agreement to acquire certain assets and an exclusive license for Machinify Auth, a proven AI software platform.
This acquisition aims to enhance Evolent's specialty condition management platform through AI-enabled clinical workflow automation.
Machinify's technology uses machine learning, large language models, and data analytics to improve clinical quality, speed, and consistency.
Expected benefits include increased first-pass approvals, streamlined data collection, and reduced clinician workforce time by 55%.
The acquisition, deemed neutral to Adjusted EBITDA in the first year, is expected to close in Q3 2024.
Evolent Health, Inc. (NYSE: EVH) has announced a strategic partnership with digital cancer care platform Careology to enhance cancer care in the U.S. This collaboration aims to provide more coordinated, connected, and empowered journeys for individuals living with cancer. By integrating Careology's digital cancer care technology into Evolent's comprehensive care navigation services, the joint platform will offer personalized information, tools, and support to help patients manage their diagnoses and treatment regimens more effectively. The partnership comes at a important time as global cancer rates are expected to increase significantly, and the U.S. faces challenges such as rising costs and drug shortages in cancer care.
Evolent Health, Inc. announced strong first quarter results, with a revenue increase of 49.6% to $639.7 million and an Adjusted EBITDA of $54.1 million. The company raised its revenue outlook for full year 2024 and reiterated its Adjusted EBITDA guidance. Evolent also highlighted new revenue agreements and an exclusive partnership with Careology. Despite a net loss of $(25.2) million, the CEO remains optimistic about the company's growth potential.
FAQ
What is the current stock price of Evolent Health (EVH)?
What is the market cap of Evolent Health (EVH)?
